Abstract
Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkins lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under preclinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.
Keywords: Radioimmunotherapy, radiolabeled antibody, solid tumor, antigen, non-Hodgkins, lymphoma, Zevalin, 131I tositumomab, Bexxar, Trastuzumab, Cetuximab, Panitumumab, Bevacizumab, DNA single strand breaks, double strand breaks, relative biological effectiveness, antibody dependent cellular cytotoxicity, complement dependent cytotoxicity, Rituximab, Tositumomab, Carcinoembryonic Antigen, Labetuzuma, Mucin 1, Tenascin-C, Ketoconazole, vincristine, Doxorubicin, Filgrastim, Carbonic Anhydrase Isotype IX, Prostate-Specific Membrane Antigen, Ganglioside 2, Epidermal Growth Factor, DNA/histone H1 Associated Protein, Melanin, Tumor Associated Glycoprotein, Mesenchymal Epithelial Transition Factor, Hepatocyte Growth Factor Receptor, anti-neuropilin, tumor endothelial marker 1, 51 integrin, v3 integrin, epidermal growth factor-like domain 7
Current Drug Delivery
Title: Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Volume: 8 Issue: 1
Author(s): Hong Song and George Sgouros
Affiliation:
Keywords: Radioimmunotherapy, radiolabeled antibody, solid tumor, antigen, non-Hodgkins, lymphoma, Zevalin, 131I tositumomab, Bexxar, Trastuzumab, Cetuximab, Panitumumab, Bevacizumab, DNA single strand breaks, double strand breaks, relative biological effectiveness, antibody dependent cellular cytotoxicity, complement dependent cytotoxicity, Rituximab, Tositumomab, Carcinoembryonic Antigen, Labetuzuma, Mucin 1, Tenascin-C, Ketoconazole, vincristine, Doxorubicin, Filgrastim, Carbonic Anhydrase Isotype IX, Prostate-Specific Membrane Antigen, Ganglioside 2, Epidermal Growth Factor, DNA/histone H1 Associated Protein, Melanin, Tumor Associated Glycoprotein, Mesenchymal Epithelial Transition Factor, Hepatocyte Growth Factor Receptor, anti-neuropilin, tumor endothelial marker 1, 51 integrin, v3 integrin, epidermal growth factor-like domain 7
Abstract: Radioimmunotherapy of solid tumors remains a challenge despite the tremendous success of 90Y ibritumomab tiuxetan (Zevalin) and 131I Tositumomab (Bexxar) in treating non-Hodgkins lymphoma. For a variety of reasons, clinical trials of radiolabeled antibodies against solid tumors have not led to responses equivalent to those seen against lymphoma. In contrast, promising responses have been observed with unlabeled antibodies that target solid tumor receptors associated with cellular signaling pathways. These observations suggest that anti-tumor efficacy of the carrier antibody might be critical to achieving clinical responses. Here, we review and compare tumor antigens targeted by radiolabeled antibodies and unlabeled antibodies used in immunotherapy. The review shows that the trend for radiolabeled antibodies under preclinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor.
Export Options
About this article
Cite this article as:
Song Hong and Sgouros George, Radioimmunotherapy of Solid Tumors: Searching for the Right Target, Current Drug Delivery 2011; 8 (1) . https://dx.doi.org/10.2174/156720111793663651
DOI https://dx.doi.org/10.2174/156720111793663651 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Longevity Pathways: HSF1 and FoxO Pathways, a New Therapeutic Target to Prevent Age-Related Diseases
Current Aging Science Review of Procedures Used for the Extraction of Anti-Cancer Compounds from Tropical Plants
Anti-Cancer Agents in Medicinal Chemistry Inflammasome and Atherogenesis
Current Pharmaceutical Design Discovery of Novel HDAC Inhibitors by Structure-based Optimization of Cinnamic Hydroxamic Scaffold
Letters in Drug Design & Discovery Co-delivery of Plasmid DNA and Antisense Oligodeoxyribonucleotide into Human Carcinoma Cells by Cationic Liposomes
Current Pharmaceutical Biotechnology Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Current Pharmaceutical Biotechnology From Bone Marrow Transplantation to Cellular Therapies: Possible Therapeutic Strategies in Managing Autoimmune Disorders
Current Pharmaceutical Design Role of miRNAs in Coronary Artery Disease
Current Signal Transduction Therapy Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) The Role of the Methoxyphenol Apocynin, a Vascular NADPH Oxidase Inhibitor, as a Chemopreventative Agent in the Potential Treatment of Cardiovascular Diseases
Current Vascular Pharmacology New Molecular and Cellular Targets for Chemoprevention and Treatment of Skin Tumors by Plant Polyphenols: A Critical Review
Current Medicinal Chemistry High Mobility Group Box-1 (HMGB1): A Potential Target in Therapeutics
Current Drug Targets Mechanisms to Inhibit Matrix Metalloproteinase Activity: Where are we in the Development of Clinically Relevant Inhibitors?
Recent Patents on Anti-Cancer Drug Discovery The CLCA Gene Family A Novel Family of Putative Chloride Channels
Current Genomics Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Biomarkers for Risk Assessment and Prevention of Breast Cancer
Current Cancer Drug Targets Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
Mini-Reviews in Medicinal Chemistry Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab
Recent Patents on Anti-Cancer Drug Discovery Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design